|Bid||0.00 x 56100|
|Ask||0.00 x 56000|
|Day's Range||197.15 - 202.60|
|52 Week Range||121.75 - 208.00|
|Beta (5Y Monthly)||0.49|
|PE Ratio (TTM)||37.70|
|Forward Dividend & Yield||1.40 (0.87%)|
|Ex-Dividend Date||Apr 26, 2021|
|1y Target Est||101.00|
Nektar (NKTR) signs a collaboration deal with Pfizer and Merck KGaA to develop a combination of its NKTR-255 with the latter's Bavencio for treating urothelial carcinoma.
Nektar Therapeutics Inc (NASDAQ: NKTR) has entered into a new oncology clinical collaboration with Merck KGaA (OTC: MKGAF) and Pfizer Inc (NYSE: PFE) to evaluate the maintenance regimen of NKTR-255 in combination with avelumab in bladder cancer study. The Phase 2 JAVELIN Bladder Medley study will include locally advanced or metastatic urothelial carcinoma (UC) patients. NKTR-255 is wholly owned by Nektar and is currently being evaluated in two separate clinical studies in both liquid and solid t
FRANKFURT (Reuters) -European companies playing key supporting roles in COVID-19 vaccine manufacturing are working to move production and supply chains closer to their customers to guard against trade restrictions that have interrupted supplies during the pandemic. Germany's Merck KGaA, whose Life Science unit is one of the world's largest makers of bioreactor gear and supplies, told Reuters it is pushing to spread its production network geographically so that fewer shipments have to cross customs borders. U.S. regulations in particular, which give priority to companies fulfilling U.S. government contracts, have posed a challenge for Merck as its seeks to meet soaring demand for supplies such as sterile fermentation bags and filters.